Portage Biotech PRTG Stock
Portage Biotech Price Chart
Portage Biotech PRTG Financial and Trading Overview
| Portage Biotech stock price | 0.26 USD |
| Previous Close | 3.81 USD |
| Open | 3.76 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 1100 |
| Day's Range | 3.67 - 3.85 USD |
| 52 Week Range | 2.34 - 11.07 USD |
| Volume | 9.45K USD |
| Avg. Volume | 22.07K USD |
| Market Cap | 64.57M USD |
| Beta (5Y Monthly) | 110.502464 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.52 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.5 USD |
PRTG Valuation Measures
| Enterprise Value | 52.56M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.9892473 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.37474748 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Portage Biotech Stock Price History
| Beta (5Y Monthly) | 110.502464 |
| 52-Week Change | -50.26% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.07 USD |
| 52 Week Low | 2.34 USD |
| 50-Day Moving Average | 3.32 USD |
| 200-Day Moving Average | 4.98 USD |
PRTG Share Statistics
| Avg. Volume (3 month) | 22.07K USD |
| Avg. Daily Volume (10-Days) | 22.61K USD |
| Shares Outstanding | 17.4M |
| Float | 10.55M |
| Short Ratio | 0.37 |
| % Held by Insiders | 40.61% |
| % Held by Institutions | 1.09% |
| Shares Short | 7.85K |
| Short % of Float | 0.069% |
| Short % of Shares Outstanding | 0.050% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:100 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -4.95% |
| Return on Equity (ttm) | -11.22% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -17480000 USD |
| Diluted EPS (ttm) | -1.25 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 13.1M USD |
| Total Cash Per Share (mrq) | 0.75 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 6.413 |
| Book Value Per Share (mrq) | 9.9 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9643000 USD |
| Levered Free Cash Flow (ttm) | -3721250 USD |
Profile of Portage Biotech
| Country | United States |
| State | N/A |
| City | Tortola |
| Address | Craigmuir Chambers |
| ZIP | VG1110 |
| Phone | N/A |
| Website | https://www.portagebiotech.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 6 |
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors. It also provides Nanolipogel (NLG) co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.
Q&A For Portage Biotech Stock
What is a current PRTG stock price?
Portage Biotech PRTG stock price today per share is 0.26 USD.
How to purchase Portage Biotech stock?
You can buy PRTG shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Portage Biotech?
The stock symbol or ticker of Portage Biotech is PRTG.
Which industry does the Portage Biotech company belong to?
The Portage Biotech industry is Biotechnology.
How many shares does Portage Biotech have in circulation?
The max supply of Portage Biotech shares is 19.78M.
What is Portage Biotech Price to Earnings Ratio (PE Ratio)?
Portage Biotech PE Ratio is now.
What was Portage Biotech earnings per share over the trailing 12 months (TTM)?
Portage Biotech EPS is -8.52 USD over the trailing 12 months.
Which sector does the Portage Biotech company belong to?
The Portage Biotech sector is Healthcare.
Portage Biotech PRTG included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16920.58 USD — |
-0.58
|
6.33B USD — | 16873.97 USD — | 16989.6 USD — | — - | 6.33B USD — |
| NASDAQ HealthCare IXHC | 967.78 USD — |
-1.12
|
— — | 964.91 USD — | 969.79 USD — | — - | — — |
- {{ link.label }} {{link}}